Neither the lipoprotein(a) [Lp(a)]-lowering antisense oligonucleotide nor the IL-6 inhibitor cut CV events in phase 3, but patients with high Lp(a) may still bring questions to pharmacists.
Commentary|Articles|May 22, 2026
FAQs on Mifepristone Safety, Access, Current Legislation, and the Pharmacist’s Role
Author(s)Gillian McGovern, Editor
Fact checked by: Sally Rafie, PharmD, BCPS, APH, FCCP, FCPHA
This FAQ covers current dispensing regulations, practical considerations for pharmacists, and the clinical pharmacology of mifepristone.
Advertisement
Advertisement
This FAQ was fact-checked by Sally Rafie, PharmD, APP, BCPS, FCCP, FCPhA.
Related to this article
Pharmacists make a difference in patients’ lives through MTM services.
Peptide cancer vaccines target neoantigens to boost T cells, with promising melanoma and pancreatic trials hinting at a new era in immunotherapy.
AI tools in pharmacy education risk eroding critical thinking, lab competency, and patient safety if used as substitutes for foundational learning.
The Main Street Pharmacy Access Act would let Medicare pay pharmacists for care they can already legally provide, if pharmacies have the time.
Ali A. Habib, MD, discusses how NIMBLE’s hospitalization findings complement symptom outcomes for investigational cemdisiran and highlights pharmacists’ role in vaccination tracking and infection-risk counseling.
Rather than requiring a new trial, the FDA extended evidence from carcinoma in situ to high-grade papillary-only disease, a new approach for this setting.
Pharmacists can address patient fears about fentanyl by distinguishing illicit from prescribed opioids and promoting safe, empathetic, evidence-based opioid use.
Advertisement
Advertisement